Publications by authors named "Jay Overholser"

Claim this Profile
N
Novel Chimeric CTLA-4 B-cell Epitope Peptide Vaccines Demonstrate Effective Antitumor Immunity with/without PD1/PDL1 Blockade in Multiple Syngeneic Murine Models of Breast and Colorectal Cancers.
Linlin Guo, Jay Overholser, Sarah Naylon, Stephane Roche, Nicholas Ede

Mol Cancer Ther· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction.
Jay Overholser, Linlin Guo, Pravin T P Kaumaya

J Vis Exp· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A newly discovered PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination with a dual HER-2 B-cell vaccine (B-Vaxx).
Linlin Guo, Jay Overholser, Heather Darby, Nicholas J Ede, Pravin T P Kaumaya

Oncoimmunology· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mitochondrial VDAC1: A Potential Therapeutic Target of Inflammation-Related Diseases and Clinical Opportunities.
Hang Hu, Linlin Guo, Jay Overholser, Xing Wang

Cells· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Studies of a Novel Human PD-1 B-Cell Peptide Cancer Vaccine PD1-Vaxx From BALB/c Mice to Beagle Dogs and to Non-Human Primates (Cynomolgus Monkeys).
Linlin Guo, Jay Overholser, Anthony J Good, Nicholas J Ede, Pravin T P Kaumaya

Front Oncol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model.
Pravin T P Kaumaya, Linlin Guo, Jay Overholser, Manuel L Penichet, Tanios Bekaii-Saab

Oncoimmunology· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors.
Tanios Bekaii-Saab, Robert Wesolowski, Daniel H Ahn, Christina Wu, Amir Mortazavi, Jay Overholser

Clin Cancer Res· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC).
Jay Overholser, Kristen Henkins Ambegaokar, Siobhan M Eze, Eduardo Sanabria-Figueroa, Rita Nahta

Vaccines (Basel)· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IGF-1R peptide vaccines/mimics inhibit the growth of BxPC3 and JIMT-1 cancer cells and exhibit synergistic antitumor effects with HER-1 and HER-2 peptides.
Kevin Chu Foy, Megan J Miller, Jay Overholser, Siobhan M Donnelly, Rita Nahta

Oncoimmunology· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells.
Megan Jo Miller, Kevin C Foy, Jay P Overholser, Rita Nahta, Pravin Tp Kaumaya

Oncoimmunology· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth in vitro and in vivo.
Kevin Chu Foy, Ruthie M Wygle, Megan J Miller, Jay P Overholser, Tanios Bekaii-Saab

J Immunol· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability.
Fang Liao, Jacqueline F Doody, Jay Overholser, Bridget Finnerty, Rajiv Bassi

Cancer Res· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis